Increased Risk of Mother‐to‐Infant Transmission of Hepatitis C Virus by Intrapartum Infantile Exposure to Maternal Blood

Steininger, Christoph; Kundi, Michael; Jatzko, Gerlinde; Kiss, Herbert; Lischka, A; Holzmann, Heidemarie

doi:10.1086/367704

Cited by 103 publications

(65 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…166 High maternal viral load (>600,000 IU/ml), invasive fetal monitoring, prolonged rupture of membranes, and fetal anoxia at the time of delivery are factors that enhance transmission. 85,167 Elective cesarean section is not required for women with HCV infection and breast-feeding does not promote transmission. However, it is prudent to avoid breast-feeding if the nipples are bleeding, if mastitis is present or if the mother is experiencing a flare of hepatitis with jaundice.…”

Section: Hepatitis C In Childrenmentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of these DAA in India at a relatively affordable price has led to great optimism about prospects of cure for these patients as not only will they provide higher efficacy, but combination DAAs as all-oral regimen will result in lower side effects than were seen with pegylated interferon alfa and ribavirin therapy. Availability of these newer DAAs has necessitated revision of INASL guidelines for the treatment of HCV published in 2015. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. The availability of combination DAA therapy has simplified therapy of HCV with decreased reliance of evaluation for monitoring viral kinetics or drug related side effects. ( J CLIN EXP HEPATOL 2016;6:119-145) T here have been revolutionary changes in the management of chronic hepatitis C (CH-C) over the last few years. Pegylated interferon alfa (Peg-IFNa) plus ribavirin (RBV) therapy, which till the recent past was the standard of care, has been eclipsed by the arrival of newer directly acting antiviral agents (DAAs). Not only do the DAAs have better efficacy, they are also associated with lower side effects, have better tolerability, a shorter duration of therapy, and have simpler administration.In the recent guidelines issued by the American Association for the study of Liver Diseases (AASLD), in collaboration with the Infectious Diseases Society of America 1 and the European Association for Study of the Liver z (EASL), 2 the role of Peg-IFNa/RBV therapy in the management of HCV has been relegated to second-line, backup status. These newer guidelines, however, cannot be implemented in India as many of the recommended drugs are yet to be marketed in India. Other considerations for the treatment of HCV in India are a predominance of

show abstract

Section: Hepatitis C In Childrenmentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

“…HCV RNA-positive mothers (usually injecting drug users) have an approximately 5% risk of transmitting the virus to their children [59]. Out of 160 mothers infected via anti-D, only 2 passed the infection on to their children and none to their spouses.…”

Section: Transmissibilitymentioning

confidence: 99%

Hepatitis C Virus (HCV)

Fard

Sibrowski

Möllmann

et al. 2003

Transfus Med Hemother

View full text Add to dashboard Cite

1.1 Characteristics of HCV HCV is the sole virus species of the genus Hepacivirus which, together with the genera Flavivirus and Pestivirus, constitutes the Flaviviridae family of viruses [1, 2]. The genera Hepacivirus and Pestivirus are structurally and biologically more closely related to one another than to the genus Flavivirus. Unlike Flavivirus, neither requires arthropods as vectors, and both may cause persistent infections in mammals. HCV is similar to the GB virus type B (GBV-B) that causes hepatitis in tamarin monkeys. Less closely related to HCV are GBV-A in various New World monkeys and GBV-C in humans [2], which to date has no known pathogenicity. The virus particles of Flaviviridae are surrounded by a lipid envelope in which at least two glycosylated surface proteins are anchored: E1 and E2 in the case of the genera Hepacivirus and Pestivirus, M and E in the case of the genus Flavivirus. (Pestiviruses additionally contain an E^rns). The viral envelope encloses a core particle formed from core protein and the single- stranded genome RNA with approximately 9,600 bases (in the case of HCV). Since only modest amounts of HCV can be isolated from plasma, the structure of the virus particles has not yet been exhaustively investigated. The hypothetical model in figure 1 has been inferred from knowledge about other Flaviviridae. ...

show abstract

“…5% [1]. Es gibt jedoch unterschiedliche Angaben über den Zeitpunkt der Übertragung.In einigen Studien wird eine In-utero-Infektion des Kindes beschrieben [1,2,3], andere Autoren gehen von einer Übertragung des Virus unter der Entbindung durch den Kontakt der kindlichen Schleimhäute mit virushaltigen Körperflüssigkeiten der Mutter aus [4,5].Das Infektionsrisiko durch das Stillen wird kontrovers diskutiert.Einige Autoren fanden HCV-RNA in Colostrum (frühe Milch bis zum 4.Tag post partum), ohne dass eines der mit diesen Milchen gestillten Kinder infiziert wurde [6]. In anderen Studien konnte in keiner untersuchten Milchprobe HCV-RNA nachgewiesen werden [7,8].…”

Section: Schlüsselwörterunclassified

Die chronische Hepatitis C der Mutter ist keine Kontraindikation f�r das Stillen

Polywka

Laufs

2003

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschu

View full text Add to dashboard Cite

Increased Risk of Mother‐to‐Infant Transmission of Hepatitis C Virus by Intrapartum Infantile Exposure to Maternal Blood

Cited by 103 publications

References 33 publications

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Hepatitis C Virus (HCV)

Die chronische Hepatitis C der Mutter ist keine Kontraindikation f�r das Stillen

Contact Info

Product

Resources

About